Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Novo Nordisk
Thursday December 18, 8:00 am ET
NEW HAVEN, Conn., Dec. 18 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has licensed its HAP(TM) Technology to Novo Nordisk A/S (NYSE: NVO - News) for use in a drug development program. Under the terms of the agreement, Novo Nordisk will pay Genaissance license and service fees, including fees for genotyping clinical samples. Genaissance will have certain rights to develop and commercialize specified diagnostic products and services.
ADVERTISEMENT
"We are pleased that Novo Nordisk chose our HAP(TM) Technology to address their pharmacogenomic need," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Novo Nordisk has been utilizing our Good Laboratory Practices DNA and genotyping services and this agreement expands the scope of our work with them, demonstrating how our various pharmacogenomic capabilities can benefit our customer base."
About Novo Nordisk
Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,700 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO.' For further company information visit www.novonordisk.com |
